

Amendments to the Claims

1. (currently amended) An isolated nucleic acid molecule which encodes a peptide that can inhibit cell division, wherein ~~characterised in that the nucleic acid molecule is selected from the following group:~~

- i) a nucleic acid molecule comprising the nucleic acid sequence presented in ~~figure 6~~ SEQ ID NO: 1;
- ii) a nucleic acid molecule as represented by the sequence presented in ~~figure 6~~ SEQ ID NO: 1 which has been modified by addition, deletion or substitution of at least one nucleotide base within at least one codon to encode a variant peptide which has cell-cycle inhibitory activity;
- iii) a nucleic acid molecule which hybridizes to the sequence in (i) or (ii); ~~and/or~~
- iv) a nucleic acid molecule comprising a nucleic acid sequence which is degenerate as a result of the genetic code to the sequences identified in (i)-(iii); ~~for the manufacture of a medicament for use in the treatment of diseases or conditions which would benefit from an inhibition of cell division.~~

2. (currently amended) A peptide encoded by the nucleic acid according to Claim 1, wherein the peptide can inhibit ~~for the manufacture of a medicament for use in the treatment of diseases or conditions which would benefit from the inhibition of cell division or angiogenesis.~~

3. (canceled)

4. (currently amended) A The peptide according to ~~Claim 2 or 3~~ claim 2, wherein the peptide can treat ~~said disease is selected from the group consisting of:~~ cancer; psoriasis; neovascular glaucoma; rheumatoid arthritis; or diabetic retinopathy.

5. – 6. (canceled)

7. (currently amended) A The peptide according to ~~Claim 6~~ claim 4, wherein said psoriatic condition is ~~selected from the group consisting of:~~ nail psoriasis; scalp psoriasis; plaque psoriasis; pustular psoriasis; guttate psoriasis; inverse psoriasis; erythrodermic psoriasis; or psoriatic arthritis.

8. (currently amended) A The peptide ~~according to any of Claims 2-7~~ of claim 2, wherein said peptide comprises ~~an~~ the amino acid sequence, ~~or part thereof, consisting of the amino acid sequence~~ ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

9. (currently amended) A The peptide according to Claim 8, wherein said peptide is a peptide consisting of the amino acid sequence ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

10. (currently amended) A The peptide ~~according to any of Claims 2-9~~ of claim 2, wherein said peptide is a fragment of ~~the peptide~~ ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

11. (currently amended) A The peptide ~~according to any of Claims 2-10~~ of claim 2, wherein said peptide is acetylated.

12. (currently amended) A The peptide according to Claim 11, wherein said acetylation is to ~~the~~ an amino terminus of said peptide.

13. (currently amended) A The peptide ~~according to any of Claims 2-12~~ of claim 2, wherein said peptide is amidated.

14. (currently amended) A The peptide according to Claim 13, wherein said amidation is to ~~the~~ a carboxyl-terminus of said peptide.

15. (currently amended) A The peptide ~~according to any of Claims 2-10~~ of claim 2, wherein said peptide, ~~or fragment thereof,~~ is modified by both acetylation and amidation.

16. (currently amended) ~~A~~ The peptide according to any of Claims 2-15 of claim 2, wherein said peptide is modified by cyclisation.
17. (currently amended) An agent comprising two or more peptides of claim 2, ~~according to any of Claims 2-16~~ wherein said agent has cell-cycle inhibitory activity.
18. (currently amended) ~~An~~ The agent according to Claim 17 of claim 17, wherein said two or more peptides are linked by a linker molecule.
19. (currently amended) ~~An~~ The agent according to Claim 17 or 18 of claim 17, wherein said agent comprises a plurality of peptides.
20. (currently amended) ~~An~~ The agent according to Claim 19 of claim 19, wherein said agent comprises 3, 4, 5, 6, 7, 8, 9, or 10 peptides linked together as an oligomeric peptide.
21. (currently amended) ~~An~~ The agent according to Claim 17 or 18 of claim 17, wherein said peptide has greater than 10 peptides.
22. (currently amended) ~~An~~ The agent according to Claim 17 or 18 of claim 17, wherein said agent is a dimer of two peptides.
23. (currently amended) ~~An~~ The agent according to any of Claims 17-22 of claim 18, wherein said linker is a peptide linking molecule.
24. (currently amended) ~~An~~ The agent according to Claim 23 of claim 23, wherein said peptide linking molecule comprises at least one amino acid residue which links at least two peptides.
25. (currently amended) ~~An~~ The agent according to Claim 23 or 24 of claim 24, wherein said peptide linking molecule comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues.

26. (currently amended) ~~An~~ The agent according to Claim 23 of claim 23, wherein said linking molecule comprises more than 10 amino acid residues.

27. (currently amended) ~~An~~ The agent according to any of Claims 17-26 of claim 17, wherein said agent is a fusion protein comprising an inframe translational fusion.

28. (canceled)

29. (currently amended) A pharmaceutical composition comprising the an agent of claim 17 ~~according to any of Claims 17-27~~.

30. (currently amended) A vector comprising a the nucleic acid molecule of claim 1 ~~which encodes a peptide and/or agent according to any of Claims 2-27~~.

31. (currently amended) A cell transformed/transfected with a the nucleic acid molecule of claim 1 ~~according to Claim 1 or a vector according to Claim 30~~.

32. (currently amended) A non-human, transgenic animal ~~characterised in that said animal incorporates a~~ comprising the nucleic acid molecule of claim 1 encoding a peptide and/or agent ~~according to any of Claims 2-27~~.

33. (currently amended) A combined preparation comprising a the peptide/agent according to any of Claims 2-27 of claim 2 and at least one cytotoxic agent.

34. (currently amended) A combined preparation comprising a the peptide/agent according to any of Claims 2-27 of claim 2 and at least one anti-angiogenic agent.

35. (currently amended) A method to treat an animal which would benefit from inhibition of cell-division comprising:

- i) administering an effective amount of the peptide of claim 2 ~~an agent comprising a peptide/agent according to any of Claims 2-27,~~ to ~~an~~ the animal to be treated;
- ii) ~~monitoring the effects of said agent~~ peptide on the inhibition of cell-division.

36. (currently amended) A The method according to Claim of claim 35 wherein said treatment is the inhibition of tumour development.

37. (currently amended) A method of treating an animal which would benefit from inhibition of cell-division, comprising administering an effective amount of the according to Claim 35 or 36 of claim 35, wherein said agent is a nucleic acid molecule of claim 1 to the animal according to Claim 1 or a vector according to Claim 30.

38. (currently amended) An imaging agent comprising a the peptide of claim 2 ~~agent according to any of Claims 2-27.~~

39. (currently amended) A peptide comprising the amino acid sequence ARYYSALRHYINLITRQRT (SEQ ID NO: 2), or a variant peptide wherein said sequence is modified by addition, deletion of substitution of at least one amino acid residue, ~~for use as a pharmaceutical agent.~~

40. (currently amended) A pharmaceutical composition comprising the peptide of claim 39 a ~~peptide according to Claim 39.~~